Article Text

AB0574 Evaluation of the efficacy of tocilizumab toward the patients with active rheumatoid arthritis of nagasaki prefecture, japan
  1. S.-Y. Kawashiri1,
  2. Y. Ueki2,
  3. K. Migita3,
  4. N. Matsuoka4,
  5. A. Mizokami5,
  6. M. Mine6,
  7. K. Fujikawa7,
  8. T. Aramaki8,
  9. H. Nakamura1,
  10. K. Eguchi9,
  11. A. Kawakami1
  1. 1Department of Immunology and Rheumatology, Nagasaki University, Nagasaki
  2. 2Center for Rheumatic Disease, Sasebo Chuo Hospital, Sasebo
  3. 3Department of General Internal Medicine, NHO National Nagasaki Medical Center, Omura
  4. 4Department of Rheumatology, Nagasaki Medical Hospital of Rheumatology
  5. 5Department of Internal Medicine, Nagasaki Municipal Hospital, Nagasaki
  6. 6Center for Rheumatic Disease, Suga Orthopedic Hospital
  7. 7Department of Internal Medicine, Isahaya Health Insurance General Hospital, Isahaya
  8. 8Department of Internal Medicine, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki
  9. 9Department of Internal Medicine, Sasebo City General Hospital, Sasebo, Japan


Background Tocilizumab (TCZ) is a humanized anti-interleukin 6 receptor (IL-6R) monoclonal antibody and it was approved in Japan as an antirheumatic drugs in 2008. Evidence of the efficacy of TCZ in real-world RA patients is still few as compared with tumour necrosis factor (TNF) inhibitors.

Objectives We have tried to evaluate the efficacy of TCZ in patients with RA during the 3 years after an approval in 2008 at Nagasaki prefecture, Japan.

Methods One hundred fifty-two RA patients at Nagasaki prefecture, Japan, who has received 8 mg/kg of TCZ every 4 weeks during 3 years, were consecutively enrolled in this study. Ninety-nine patients had evaluable data for 1 year at present. We have focused on the efficacy of TCZ in the present study trying to evaluate the clinical response of disease activity score (DAS) 28, simplified disease activity index (SDAI), clinical disease activity index (CDAI), Boolean approach and Health Assessment Questionnaire (HAQ) by last observation carried forward (LOCF) methodology toward these 99 patients, respectively.

Results The mean age, disease duration and clinical disease activity at baseline were 58 years-old, 11 years, DAS28-ESR: 5.5, SDAI: 28.7 and CDAI: 25.5, respectively. Fifty-nine percent of the patients had received TNF inhibitors before introduction of TCZ. Although most of the patients were active as well as established disease at baseline, the continuation rate at 1 year was superior as 81.1%. A rate of clinical remission at 1 year of DAS28-ESR, SDAI, CDAI and Boolean-based definition was 49.5%, 17.2%, 13.1% and 13.1%, respectively. There was a clear relation of the rate of clinical remission with shorter disease duration (less than 2 years) or no previous history of TNF inhibitors. Furthermore, low HAQ at baseline was the only variable to be associated with CDAI remission (OR [95% CI]: 0.34 [0.09-0.88], p=0.06) and HAQ remission (OR [95% CI]: 0.17 [0.03-0.50], p<0.01) at 1 year defined by logistic regression analysis.

Conclusions The present study shows an excellent therapeutic efficacy as well as the characterisitic of patients being achieved in remission by TCZ in the real-world clinical practice.

  1. Kawashiri SY, et al. In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline. Mod Rheumatol. 2011;21:370-4.

  2. Kawashiri SY, et al. Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index. Mod Rheumatol. 2011;21:365-9.

Disclosure of Interest None Declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.